Lakefront Biotherapeutics | GLPG - Debt


Lakefront Biotherapeutics reported EUR6.44M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
argenx SE USD 47M 160K Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Biogen USD 7.69B 398.3M Sep/2026
Genmab DKK 5.35B 5.2B Mar/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
GlaxoSmithKline GBP 18.24B 818M Jun/2026
GRIFOLS EUR 9.24B 723M Sep/2026
Hikma Pharmaceutical USD 1.6B 46M Dec/2025
Incyte USD 38.27M 1.16M Jun/2026
Merck EUR 12.3B 264M Jun/2026
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
Novartis USD 49.01B 2.02B Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 23.58B 3.56B Jun/2026
UCB EUR 3.03B 12M Dec/2024
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026